Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

Background: Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evalu...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Front Pharmacol
Główni autorzy: Facchini, Gaetano, Caffo, Orazio, Ortega, Cinzia, D'Aniello, Carmine, Di Napoli, Marilena, Cecere, Sabrina C., Della Pepa, Chiara, Crispo, Anna, Maines, Francesca, Ruatta, Fiorella, Iovane, Gelsomina, Pisconti, Salvatore, Montella, Maurizio, Berretta, Massimiliano, Pignata, Sandro, Cavaliere, Carla
Format: Artigo
Język:Inglês
Wydane: Frontiers Media S.A. 2016
Hasła przedmiotowe:
Pharmacology
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4870277/
https://ncbi.nlm.nih.gov/pubmed/27242530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00123
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy